Article

Generic versions of oxybutynin gain approval for OAB

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.

Related Content
© 2025 MJH Life Sciences

All rights reserved.